24 results on '"Gobeau, Nathalie"'
Search Results
2. Antimalarial activity of single-dose DSM265, a novel plasmodium dihydroorotate dehydrogenase inhibitor, in patients with uncomplicated Plasmodium falciparum or Plasmodium vivax malaria infection: a proof-of-concept, open-label, phase 2a study
- Author
-
Llanos-Cuentas, Alejandro, Casapia, Martin, Chuquiyauri, Raúl, Hinojosa, Juan-Carlos, Kerr, Nicola, Rosario, Maria, Toovey, Stephen, Arch, Robert H, Phillips, Margaret A, Rozenberg, Felix D, Bath, Jade, Ng, Caroline L, Cowell, Annie N, Winzeler, Elizabeth A, Fidock, David A, Baker, Mark, Möhrle, Jörg J, Hooft van Huijsduijnen, Rob, Gobeau, Nathalie, Araeipour, Nada, Andenmatten, Nicole, Rückle, Thomas, and Duparc, Stephan
- Published
- 2018
- Full Text
- View/download PDF
3. DSM265 for Plasmodium falciparum chemoprophylaxis: a randomised, double blinded, phase 1 trial with controlled human malaria infection
- Author
-
Sulyok, Mihály, Rückle, Thomas, Roth, Alexandra, Mürbeth, Raymund E, Chalon, Stephan, Kerr, Nicola, Samec, Sonia Schnieper, Gobeau, Nathalie, Calle, Carlos Lamsfus, Ibáñez, Javier, Sulyok, Zita, Held, Jana, Gebru, Tamirat, Granados, Patricia, Brückner, Sina, Nguetse, Christian, Mengue, Juliana, Lalremruata, Albert, Sim, B Kim Lee, Hoffman, Stephen L, Möhrle, Jörg J, Kremsner, Peter G, and Mordmüller, Benjamin
- Published
- 2017
- Full Text
- View/download PDF
4. Safety, tolerability, pharmacokinetics, and activity of the novel long-acting antimalarial DSM265: a two-part first-in-human phase 1a/1b randomised study
- Author
-
McCarthy, James S, Lotharius, Julie, Rückle, Thomas, Chalon, Stephan, Phillips, Margaret A, Elliott, Suzanne, Sekuloski, Silvana, Griffin, Paul, Ng, Caroline L, Fidock, David A, Marquart, Louise, Williams, Noelle S, Gobeau, Nathalie, Bebrevska, Lidiya, Rosario, Maria, Marsh, Kennan, and Möhrle, Jörg J
- Published
- 2017
- Full Text
- View/download PDF
5. Ensemble modeling highlights importance of understanding parasite-host behavior in preclinical antimalarial drug development
- Author
-
Burgert, Lydia, Rottmann, Matthias, Wittlin, Sergio, Gobeau, Nathalie, Krause, Andreas, Dingemanse, Jasper, Möhrle, Jörg J., and Penny, Melissa A.
- Published
- 2020
- Full Text
- View/download PDF
6. Development and application of a PBPK modeling strategy to support antimalarial drug development.
- Author
-
Abla, Nada, Howgate, Eleanor, Rowland‐Yeo, Karen, Dickins, Maurice, Bergagnini‐Kolev, Mackenzie C., Chen, Kuan‐Fu, McFeely, Savannah, Bonner, Jennifer J., Santos, Laura G. A., Gobeau, Nathalie, Burt, Howard, Barter, Zoe, Jones, Hannah M., Wesche, David, Charman, Susan A., Möhrle, Jörg J., Burrows, Jeremy N., and Almond, Lisa M.
- Subjects
DRUG development ,DRUG interactions ,ANTIMALARIALS ,SCIENTIFIC community ,PHARMACOKINETICS ,WORLD health - Abstract
As part of a collaboration between Medicines for Malaria Venture (MMV), Certara UK and Monash University, physiologically‐based pharmacokinetic (PBPK) models were developed for 20 antimalarials, using data obtained from standardized in vitro assays and clinical studies within the literature. The models have been applied within antimalarial drug development at MMV for more than 5 years. During this time, a strategy for their impactful use has evolved. All models are described in the supplementary material and are available to researchers. Case studies are also presented, demonstrating real‐world development and clinical applications, including the assessment of the drug–drug interaction liability between combination partners or with co‐administered drugs. This work emphasizes the benefit of PBPK modeling for antimalarial drug development and decision making, and presents a strategy to integrate it into the research and development process. It also provides a repository of shared information to benefit the global health research community. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
7. The Parasite Reduction Ratio (PRR) Assay Version 2: Standardized Assessment of Plasmodium falciparum Viability after Antimalarial Treatment In Vitro.
- Author
-
Walz, Annabelle, Duffey, Maëlle, Aljayyoussi, Ghaith, Sax, Sibylle, Leroy, Didier, Besson, Dominique, Burrows, Jeremy N., Cherkaoui-Rbati, Mohammed H., Gobeau, Nathalie, Westwood, Marie-Anne, Siethoff, Christoph, Gamo, Francisco-Javier, Mäser, Pascal, and Wittlin, Sergio
- Subjects
PLASMODIUM falciparum ,PARASITES ,PLASMODIUM ,QUALITY control - Abstract
With artemisinin-resistant Plasmodium falciparum parasites emerging in Africa, the need for new antimalarial chemotypes is persistently high. The ideal pharmacodynamic parameters of a candidate drug are a rapid onset of action and a fast rate of parasite killing or clearance. To determine these parameters, it is essential to discriminate viable from nonviable parasites, which is complicated by the fact that viable parasites can be metabolically inactive, whilst dying parasites can still be metabolically active and morphologically unaffected. Standard growth inhibition assays, read out via microscopy or [
3 H] hypoxanthine incorporation, cannot reliably discriminate between viable and nonviable parasites. Conversely, the in vitro parasite reduction ratio (PRR) assay is able to measure viable parasites with high sensitivity. It provides valuable pharmacodynamic parameters, such as PRR, 99.9% parasite clearance time (PCT99.9% ) and lag phase. Here we report the development of the PRR assay version 2 (V2), which comes with a shorter assay duration, optimized quality controls and an objective, automated analysis pipeline that systematically estimates PRR, PCT99.9% and lag time and returns meaningful secondary parameters such as the maximal killing rate of a drug (Emax ) at the assayed concentration. These parameters can be fed directly into pharmacokinetic/pharmacodynamic models, hence aiding and standardizing lead selection, optimization, and dose prediction. [ABSTRACT FROM AUTHOR]- Published
- 2023
- Full Text
- View/download PDF
8. A pharmacokinetic–pharmacodynamic model for chemoprotective agents against malaria.
- Author
-
Cherkaoui‐Rbati, Mohammed H., Andenmatten, Nicole, Burgert, Lydia, Egbelowo, Oluwaseun F., Fendel, Rolf, Fornari, Chiara, Gabel, Michael, Ward, John, Möhrle, Jörg J., and Gobeau, Nathalie
- Subjects
MALARIA ,DIHYDROOROTATE dehydrogenase ,GLUCOSE-6-phosphate dehydrogenase deficiency ,PREGNANT women ,PHARMACODYNAMICS ,MOSQUITO control - Abstract
Chemoprophylactics are a vital tool in the fight against malaria. They can be used to protect populations at risk, such as children younger than the age of 5 in areas of seasonal malaria transmission or pregnant women. Currently approved chemoprophylactics all present challenges. There are either concerns about unacceptable adverse effects such as neuropsychiatric sequalae (mefloquine), risks of hemolysis in patients with G6PD deficiency (8‐aminoquinolines such as tafenoquine), or cost and daily dosing (atovaquone–proguanil). Therefore, there is a need to develop new chemoprophylactic agents to provide more affordable therapies with better compliance through improving properties such as pharmacokinetics to allow weekly, preferably monthly, dosing. Here we present a pharmacokinetic–pharmacodynamic (PKPD) model constructed using DSM265 (a dihydroorotate dehydrogenase inhibitor with activity against the liver schizonts of malaria, therefore, a prophylaxis candidate). The PKPD model mimics the parasite lifecycle by describing parasite dynamics and drug activity during the liver and blood stages. A major challenge is the estimation of model parameters, as only blood‐stage parasites can be observed once they have reached a threshold. By combining qualitative and quantitative knowledge about the parasite from various sources, it has been shown that it is possible to infer information about liver‐stage growth and its initial infection level. Furthermore, by integrating clinical data, the killing effect of the drug on liver‐ and blood‐stage parasites can be included in the PKPD model, and a clinical outcome can be predicted. Despite multiple challenges, the presented model has the potential to help translation from preclinical to late development for new chemoprophylactic candidates. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
9. Safety, Tolerability, and Parasite Clearance Kinetics in Controlled Human Malaria Infection after Direct Venous Inoculation of Plasmodium falciparum Sporozoites: A Model for Evaluating New Blood-Stage Antimalarial Drugs.
- Author
-
Chughlay, M. Farouk, Chalon, Stephan, El Gaaloul, Myriam, Gobeau, Nathalie, Möhrle, Jörg J., Berghmans, Pieter-Jan, Van Leuven, Katrin, Marx, Michael W., Rosanas-Urgell, Anna, Flynn, Julia, Escoffier, Emilie, Izquierdo-Juncás, Daniel, Jansen, Bastiaan, Mitov, Venelin, Kümmel, Anne, Van Geertruyden, Jean-Pierre, and Barnes, Karen I.
- Published
- 2022
- Full Text
- View/download PDF
10. Efficient simulation of clinical target response surfaces.
- Author
-
Lill, Daniel, Kümmel, Anne, Mitov, Venelin, Kaschek, Daniel, Gobeau, Nathalie, Schmidt, Henning, and Timmer, Jens
- Subjects
COMPUTATIONAL complexity ,SEARCH algorithms ,EXPERIMENTAL design ,CLINICAL trials ,PHARMACOKINETICS - Abstract
Simulation of combination therapies is challenging due to computational complexity. Either a simple model is used to simulate the response for many combinations of concentration to generate a response surface but parameter variability and uncertainty are neglected and the concentrations are constant—the link to the doses to be administered is difficult to make—or a population pharmacokinetic/pharmacodynamic model is used to predict the response to combination therapy in a clinical trial taking into account the time‐varying concentration profile, interindividual variability (IIV), and parameter uncertainty but simulations are limited to only a few selected doses. We devised new algorithms to efficiently search for the combination doses that achieve a predefined efficacy target while taking into account the IIV and parameter uncertainty. The result of this method is a response surface of confidence levels, indicating for all dose combinations the likelihood of reaching the specified efficacy target. We highlight the importance to simulate across a population rather than focus on an individual. Finally, we provide examples of potential applications, such as informing experimental design. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
11. Antimalarial Activity of Artefenomel Against Asexual Parasites and Transmissible Gametocytes During Experimental Blood-Stage Plasmodium vivax Infection.
- Author
-
Collins, Katharine A, Abd-Rahman, Azrin N, Marquart, Louise, Ballard, Emma, Gobeau, Nathalie, Griffin, Paul, Chalon, Stephan, Möhrle, Jörg J, and McCarthy, James S
- Subjects
PLASMODIUM vivax ,CLINICAL trial registries ,GERM cells ,PARASITES ,MALARIA prevention ,TRYPANOSOMA cruzi ,TRYPANOSOMA ,DRUG therapy for malaria ,FOLIC acid antagonists ,PROTOZOA ,RESEARCH ,ANIMAL experimentation ,RESEARCH methodology ,EVALUATION research ,MALARIA ,HYDROCARBONS ,PEROXIDES ,COMPARATIVE studies ,RESEARCH funding ,ANTIMALARIALS ,MOSQUITOES ,PHARMACODYNAMICS - Abstract
Background: Interventions that effectively target Plasmodium vivax are critical for the future control and elimination of malaria. We conducted a P. vivax volunteer infection study to characterize the antimalarial activity of artefenomel, a new drug candidate.Methods: Eight healthy, malaria-naive participants were intravenously inoculated with blood-stage P. vivax and subsequently received a single oral 200-mg dose of artefenomel. Blood samples were collected to monitor the development and clearance of parasitemia, and plasma artefenomel concentration. Mosquito feeding assays were conducted before artefenomel dosing to investigate parasite transmissibility.Results: Initial parasite clearance occurred in all participants after artefenomel administration (log10 parasite reduction ratio over 48 hours, 1.67; parasite clearance half-life, 8.67 hours). Recrudescence occurred in 7 participants 11-14 days after dosing. A minimum inhibitory concentration of 0.62 ng/mL and minimum parasiticidal concentration that achieves 90% of maximum effect of 0.83 ng/mL were estimated, and a single 300-mg dose was predicted to clear 109 parasites per milliliter with 95% certainty. Gametocytemia developed in all participants and was cleared 4-8 days after dosing. At peak gametocytemia, 75% of participants were infectious to mosquitoes.Conclusions: The in vivo antimalarial activity of artefenomel supports its further clinical development as a treatment for P. vivax malaria.Clinical Trials Registration: NCT02573857. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
12. Seeking an optimal dosing regimen for OZ439/DSM265 combination therapy for treating uncomplicated falciparum malaria.
- Author
-
Dini, Saber, Zaloumis, Sophie G., Price, David J., Gobeau, Nathalie, Kümmel, Anne, Cherkaoui, Mohammed, Moehrle, Joerg J., McCarthy, James S., and Simpson, Julie A.
- Subjects
PARASITE life cycles ,MALARIA ,DRUG interactions ,PLASMODIUM ,DRUG administration ,DRUG therapy for malaria ,PROTOZOA ,COMBINATION drug therapy ,HETEROCYCLIC compounds ,ANTIMALARIALS ,PROBABILITY theory - Abstract
Background: The efficacy of artemisinin-based combination therapies (ACTs), the first-line treatments for uncomplicated falciparum malaria, has been declining in malaria-endemic countries due to the emergence of malaria parasites resistant to these compounds. Novel alternative therapies are needed urgently to prevent the likely surge in morbidity and mortality due to failing ACTs.Objectives: This study investigates the efficacy of the combination of two novel drugs, OZ439 and DSM265, using a biologically informed within-host mathematical model.Methods: A within-host model was developed, which accounts for the differential killing of these compounds against different stages of the parasite's life cycle and accommodates the pharmacodynamic interaction between the drugs. Data of healthy volunteers infected with falciparum malaria collected from four trials (three that administered OZ439 and DSM265 alone, and the fourth a combination of OZ439 and DSM265) were analysed. Model parameters were estimated in a hierarchical Bayesian framework.Results: The posterior predictive simulations of our model predicted that 800 mg of OZ439 combined with 450 mg of DSM265, which are within the safe and tolerable dose range, can provide above 90% cure rates 42 days after drug administration.Conclusions: Our results show that the combination of OZ439 and DSM265 can be a promising alternative to replace ACTs. Our model can be used to inform future Phase 2 and 3 clinical trials of OZ439/DSM265, fast-tracking the deployment of this combination therapy in the regions where ACTs are failing. The dosing regimens that are shown to be efficacious and within safe and tolerable limits are suggested for future investigations. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
13. The antimalarial MMV688533 provides potential for single-dose cures with a high barrier to Plasmodium falciparum parasite resistance.
- Author
-
Murithi, James M., Pascal, Cécile, Bath, Jade, Boulenc, Xavier, Gnädig, Nina F., Pasaje, Charisse Flerida A., Rubiano, Kelly, Yeo, Tomas, Mok, Sachel, Klieber, Sylvie, Desert, Paul, Jiménez-Díaz, María Belén, Marfurt, Jutta, Rouillier, Mélanie, Cherkaoui-Rbati, Mohammed H., Gobeau, Nathalie, Wittlin, Sergio, Uhlemann, Anne-Catrin, Price, Ric N., and Wirjanata, Grennady
- Subjects
PLASMODIUM falciparum ,LABORATORY mice ,MALARIA ,DRUG target ,PLASMODIUM ,PARASITES ,ANIMAL disease models ,ANTIMALARIALS - Abstract
Antimalarial advance: The need for antimalarial drugs is urgent in the face of growing resistance to existing therapies. Murithi et al. characterized MMV688533, an acylguanidine identified from compounds inhibiting known human drug targets that were screened for activity against Plasmodium falciparum. MMV688533 showed rapid in vitro killing of multiple P. falciparum strains as well as P. vivax. A single dose of MMV688533 rapidly reduced parasitemia in a P. falciparum NSG mouse model of infection, and this agent displayed favorable pharmacokinetic and toxicity profiles. MMV688533 selected for only low-grade resistance, with resistant parasites remaining sensitive to existing antimalarials. These findings suggest that MMV688533 is a promising antimalarial candidate with a low resistance risk and the promise of a single-dose cure, which merits further study. The emergence and spread of Plasmodium falciparum resistance to first-line antimalarials creates an imperative to identify and develop potent preclinical candidates with distinct modes of action. Here, we report the identification of MMV688533, an acylguanidine that was developed following a whole-cell screen with compounds known to hit high-value targets in human cells. MMV688533 displays fast parasite clearance in vitro and is not cross-resistant with known antimalarials. In a P. falciparum NSG mouse model, MMV688533 displays a long-lasting pharmacokinetic profile and excellent safety. Selection studies reveal a low propensity for resistance, with modest loss of potency mediated by point mutations in PfACG1 and PfEHD. These proteins are implicated in intracellular trafficking, lipid utilization, and endocytosis, suggesting interference with these pathways as a potential mode of action. This preclinical candidate may offer the potential for a single low-dose cure for malaria. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
14. Retrospective Analysis Using Pharmacokinetic/Pharmacodynamic Modeling and Simulation Offers Improvements in Efficiency of the Design of Volunteer Infection Studies for Antimalarial Drug Development.
- Author
-
Andrews, Kayla Ann, Owen, Joel S., McCarthy, James, Wesche, David, Gobeau, Nathalie, Grasela, Thaddeus H., and Möhrle, Jörg J.
- Subjects
DRUG development ,PHARMACOKINETICS ,RETROSPECTIVE studies ,VOLUNTEERS ,ANTIMALARIALS ,SIMULATION methods & models - Abstract
Volunteer infection studies using the induced blood stage malaria (IBSM) model have been shown to facilitate antimalarial drug development. Such studies have traditionally been undertaken in single‐dose cohorts, as many as necessary to obtain the dose‐response relationship. To enhance ethical and logistic aspects of such studies, and to reduce the number of cohorts needed to establish the dose‐response relationship, we undertook a retrospective in silico analysis of previously accrued data to improve study design. A pharmacokinetic (PK)/pharmacodynamic (PD) model was developed from initial fictive‐cohort data for OZ439 (mixing the data of the three single‐dose cohorts as: n = 2 on 100 mg, 2 on 200 mg, and 4 on 500 mg). A three‐compartment model described OZ439 PKs. Net growth of parasites was modeled using a Gompertz function and drug‐induced parasite death using a Hill function. Parameter estimates for the PK and PD models were comparable for the multidose single‐cohort vs. the pooled analysis of all cohorts. Simulations based on the multidose single‐cohort design described the complete data from the original IBSM study. The novel design allows for the ascertainment of the PK/PD relationship early in the study, providing a basis for rational dose selection for subsequent cohorts and studies. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
15. A Phase 1, Placebo-controlled, Randomized, Single Ascending Dose Study and a Volunteer Infection Study to Characterize the Safety, Pharmacokinetics, and Antimalarial Activity of the Plasmodium Phosphatidylinositol 4-Kinase Inhibitor MMV390048.
- Author
-
McCarthy, James S, Donini, Cristina, Chalon, Stephan, Woodford, John, Marquart, Louise, Collins, Katharine A, Rozenberg, Felix D, Fidock, David A, Cherkaoui-Rbati, Mohammed H, Gobeau, Nathalie, and Möhrle, Jörg J
- Subjects
DRUG therapy for malaria ,ANTIMALARIALS ,COMBINED modality therapy ,CONFIDENCE intervals ,RESEARCH funding ,STATISTICAL sampling ,TRANSFERASES ,RANDOMIZED controlled trials ,DESCRIPTIVE statistics - Abstract
Background MMV390048 is the first Plasmodium phosphatidylinositol 4-kinase inhibitor to reach clinical development as a new antimalarial. We aimed to characterize the safety, pharmacokinetics, and antimalarial activity of a tablet formulation of MMV390048. Methods A 2-part, phase 1 trial was conducted in healthy adults. Part 1 was a double-blind, randomized, placebo-controlled, single ascending dose study consisting of 3 cohorts (40, 80, 120 mg MMV390048). Part 2 was an open-label volunteer infection study using the Plasmodium falciparum induced blood-stage malaria model consisting of 2 cohorts (40 mg and 80 mg MMV390048). Results Twenty four subjects were enrolled in part 1 (n = 8 per cohort, randomized 3:1 MMV390048:placebo) and 15 subjects were enrolled in part 2 (40 mg [n = 7] and 80 mg [n = 8] cohorts). One subject was withdrawn from part 2 (80 mg cohort) before dosing and was not included in analyses. No serious or severe adverse events were attributed to MMV390048. The rate of parasite clearance was greater in subjects administered 80 mg compared to those administered 40 mg (clearance half-life 5.5 hours [95% confidence interval {CI}, 5.2–6.0 hours] vs 6.4 hours [95% CI, 6.0–6.9 hours]; P = .005). Pharmacokinetic/pharmacodynamic modeling estimated a minimum inhibitory concentration of 83 ng/mL and a minimal parasiticidal concentration that would achieve 90% of the maximum effect of 238 ng/mL, and predicted that a single 120-mg dose would achieve an adequate clinical and parasitological response with 92% certainty. Conclusions The safety, pharmacokinetics, and pharmacodynamics of MMV390048 support its further development as a partner drug of a single-dose combination therapy for malaria. Clinical Trials Registration NCT02783820 (part 1); NCT02783833 (part 2). [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
16. Population Pharmacokinetics and Pharmacodynamics of Chloroquine in a Plasmodium vivax Volunteer Infection Study.
- Author
-
Abd‐Rahman, Azrin N., Marquart, Louise, Gobeau, Nathalie, Kümmel, Anne, Simpson, Julie A., Chalon, Stephan, Möhrle, Jörg J., and McCarthy, James S.
- Subjects
PLASMODIUM vivax ,CHLOROQUINE ,BLOOD plasma ,PHARMACODYNAMICS ,PHARMACOKINETICS ,VOLUNTEERS - Abstract
Chloroquine has been used for the treatment of malaria for > 70 years; however, chloroquine pharmacokinetic (PK) and pharmacodynamic (PD) profile in Plasmodium vivax malaria is poorly understood. The objective of this study was to describe the PK/PD relationship of chloroquine and its major metabolite, desethylchloroquine, in a P. vivax volunteer infection study. We analyzed data from 24 healthy subjects who were inoculated with blood‐stage P. vivax malaria and administered a standard treatment course of chloroquine. The PK of chloroquine and desethylchloroquine was described by a two‐compartment model with first‐order absorption and elimination. The relationship between plasma and whole blood concentrations of chloroquine and P. vivax parasitemia was characterized by a PK/PD delayed response model, where the equilibration half‐lives were 32.7 hours (95% confidence interval (CI) 27.4–40.5) for plasma data and 24.1 hours (95% CI 19.0–32.7) for whole blood data. The estimated parasite multiplication rate was 17 folds per 48 hours (95% CI 14–20) and maximum parasite killing rate by chloroquine was 0.213 hour−1 (95% CI 0.196–0.230), translating to a parasite clearance half‐life of 4.5 hours (95% CI 4.1–5.0) and a parasite reduction ratio of 400 every 48 hours (95% CI 320–500). This is the first study that characterized the PK/PD relationship between chloroquine plasma and whole blood concentrations and P. vivax clearance using a semimechanistic population PK/PD modeling. This PK/PD model can be used to optimize dosing scenarios and to identify optimal dosing regimens for chloroquine where resistance to chloroquine is increasing. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
17. Setting Our Sights on Infectious Diseases.
- Author
-
De Rycker, Manu, Horn, David, Aldridge, Bree, Amewu, Richard K., Barry III, Clifton E., Buckner, Frederick S., Cook, Sarah, Ferguson, Michael A. J., Gobeau, Nathalie, Herrmann, Jennifer, Herrling, Paul, Hope, William, Keiser, Jennifer, Lafuente-Monasterio, Maria Jose, Leeson, Paul D., Leroy, Didier, Manjunatha, Ujjini H., McCarthy, James, Miles, Timothy J., and Mizrahi, Valerie
- Published
- 2020
- Full Text
- View/download PDF
18. Structure-Based and Property-Driven Optimization of N‑Aryl Imidazoles toward Potent and Selective Oral RORγt Inhibitors.
- Author
-
Hoegenauer, Klemens, Kallen, Joerg, Jiménez-Núñez, Eloísa, Strang, Ross, Ertl, Peter, Cooke, Nigel G., Hintermann, Samuel, Voegtle, Markus, Betschart, Claudia, McKay, Daniel J. J., Wagner, Juergen, Ottl, Johannes, Beerli, Christian, Billich, Andreas, Dawson, Janet, Kaupmann, Klemens, Streiff, Markus, Gobeau, Nathalie, Harlfinger, Stephanie, and Stringer, Rowan
- Published
- 2019
- Full Text
- View/download PDF
19. 977Mechanistic within-host modelling to fast-track the selection of new antimalarial combination therapies.
- Author
-
Simpson, Julie, Dini, Saber, Zaloumis, Sophie, Price, David, McCarthy, James, Cherkaoui, Mohammed, Kummel, Anne, and Gobeau, Nathalie
- Subjects
MALARIA ,DRUG development ,DRUG interactions ,PLASMODIUM ,FRAMES (Social sciences) ,RESOURCE allocation - Abstract
Background The efficacy of artemisinin-based combination therapies (ACTs), currently the first-line antimalarial treatments, is declining due to the emergence of resistance of malaria parasites to these drugs. This has led drug development initiatives to search for novel combination therapies to replace the failing ACTs. We developed a biologically informed within-host model, validated against data from volunteer infection studies, to guide critical drug development decisions. Methods A within-host model was developed, linking drug concentrations of two novel antimalarial drugs, OZ439 and DSM265, to their combined killing action and accounting for differential killing of these compounds against stages of the parasite's lifecycle. Data collected from malaria-infected volunteers treated with OZ439–DSM265 were used to estimate the model parameters in a hierarchical Bayesian framework. Posterior-predictive simulations of the model were used to determine the dosing regimen required to cure >90% patients. Results The results showed that 800 mg of OZ439 combined with 450 mg of DSM265, which are within the safe and tolerable dose range, can provide day 42 cure rates >90%, despite the estimated antagonistic interaction between the drugs. The importance of accommodating parasite age specificity of drug action was demonstrated. Conclusions The dosing regimens for the combination of OZ439-DSM265 determined from our data-informed in silico model suggest this compound may be a suitable candidate to replace failing ACTs. Key messages Assessing various scenarios within a simulation framework allows discovery of robust dosing regimens, accelerating the drug development process and ensuring efficient allocation of resources for phase 2 and 3 clinical trials. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
20. Predicting Optimal Antimalarial Drug Combinations from a Standardized Plasmodium falciparum Humanized Mouse Model.
- Author
-
Demarta-Gatsi C, Andenmatten N, Jiménez-Díaz MB, Gobeau N, Cherkaoui-Rabti MH, Fuchs A, Díaz P, Berja S, Sánchez R, Gómez H, Ruiz E, Sainz P, Salazar E, Gil-Merino R, Mendoza LM, Eguizabal C, Leroy D, Moehrle JJ, Tornesi B, and Angulo-Barturen I
- Subjects
- Animals, Mice, Plasmodium falciparum, Retrospective Studies, Peroxides, Drug Combinations, Antimalarials pharmacology, Antimalarials therapeutic use, Malaria, Falciparum drug therapy, Malaria, Falciparum parasitology
- Abstract
The development of new combinations of antimalarial drugs is urgently needed to prevent the spread of parasites resistant to drugs in clinical use and contribute to the control and eradication of malaria. In this work, we evaluated a standardized humanized mouse model of erythrocyte asexual stages of Plasmodium falciparum (PfalcHuMouse) for the selection of optimal drug combinations. First, we showed that the replication of P. falciparum was robust and highly reproducible in the PfalcHuMouse model by retrospective analysis of historical data. Second, we compared the relative value of parasite clearance from blood, parasite regrowth after suboptimal treatment (recrudescence), and cure as variables of therapeutic response to measure the contributions of partner drugs to combinations in vivo . To address the comparison, we first formalized and validated the day of recrudescence (DoR) as a new variable and found that there was a log-linear relationship with the number of viable parasites per mouse. Then, using historical data on monotherapy and two small cohorts of PfalcHuMice evaluated with ferroquine plus artefenomel or piperaquine plus artefenomel, we found that only measurements of parasite killing (i.e., cure of mice) as a function of drug exposure in blood allowed direct estimation of the individual drug contribution to efficacy by using multivariate statistical modeling and intuitive graphic displays. Overall, the analysis of parasite killing in the PfalcHuMouse model is a unique and robust experimental in vivo tool to inform the selection of optimal combinations by pharmacometric pharmacokinetic and pharmacodynamic (PK/PD) modeling., Competing Interests: The authors declare a conflict of interest. M.-B.J.-D. and I.A.-B. are co-founders and shareholders of The Art of Discovery.
- Published
- 2023
- Full Text
- View/download PDF
21. New In Vitro Interaction-Parasite Reduction Ratio Assay for Early Derisk in Clinical Development of Antimalarial Combinations.
- Author
-
Wicha SG, Walz A, Cherkaoui-Rbati MH, Bundgaard N, Kuritz K, Gumpp C, Gobeau N, Möhrle J, Rottmann M, and Demarta-Gatsi C
- Subjects
- Humans, Animals, Mice, Drug Combinations, Plasmodium falciparum, Antimalarials therapeutic use, Parasites, Malaria, Falciparum drug therapy, Malaria drug therapy
- Abstract
The development and spread of drug-resistant phenotypes substantially threaten malaria control efforts. Combination therapies have the potential to minimize the risk of resistance development but require intensive preclinical studies to determine optimal combination and dosing regimens. To support the selection of new combinations, we developed a novel in vitro-in silico combination approach to help identify the pharmacodynamic interactions of the two antimalarial drugs in a combination which can be plugged into a pharmacokinetic/pharmacodynamic model built with human monotherapy parasitological data to predict the parasitological endpoints of the combination. This makes it possible to optimally select drug combinations and doses for the clinical development of antimalarials. With this assay, we successfully predicted the endpoints of two phase 2 clinical trials in patients with the artefenomel-piperaquine and artefenomel-ferroquine drug combinations. In addition, the predictive performance of our novel in vitro model was equivalent to that of the humanized mouse model outcome. Last, our more informative in vitro combination assay provided additional insights into the pharmacodynamic drug interactions compared to the in vivo systems, e.g., a concentration-dependent change in the maximum killing effect ( E
max ) and the concentration producing 50% of the killing maximum effect (EC50 ) of piperaquine or artefenomel or a directional reduction of the EC50 of ferroquine by artefenomel and a directional reduction of Emax of ferroquine by artefenomel. Overall, this novel in vitro-in silico -based technology will significantly improve and streamline the economic development of new drug combinations for malaria and potentially also in other therapeutic areas.- Published
- 2022
- Full Text
- View/download PDF
22. Parasite Viability as a Measure of In Vivo Drug Activity in Preclinical and Early Clinical Antimalarial Drug Assessment.
- Author
-
Radohery GFR, Walz A, Gumpp C, Cherkaoui-Rbati MH, Gobeau N, Gower J, Davenport MP, Rottmann M, McCarthy JS, Möhrle JJ, Rebelo M, Demarta-Gatsi C, and Khoury DS
- Subjects
- Animals, Artesunate pharmacology, Artesunate therapeutic use, Australia, Humans, Mice, Parasitemia drug therapy, Parasitemia parasitology, Plasmodium falciparum, Antimalarials pharmacokinetics, Antimalarials therapeutic use, Artemisinins pharmacokinetics, Artemisinins therapeutic use, Malaria, Falciparum drug therapy, Parasites
- Abstract
The rate at which parasitemia declines in a host after treatment with an antimalarial drug is a major metric for assessment of antimalarial drug activity in preclinical models and in early clinical trials. However, this metric does not distinguish between viable and nonviable parasites. Thus, enumeration of parasites may result in underestimation of drug activity for some compounds, potentially confounding its use as a metric for assessing antimalarial activity in vivo . Here, we report a study of the effect of artesunate on Plasmodium falciparum viability in humans and in mice. We first measured the drug effect in mice by estimating the decrease in parasite viability after treatment using two independent approaches to estimate viability. We demonstrate that, as previously reported in humans, parasite viability declines much faster after artesunate treatment than does the decline in parasitemia (termed parasite clearance). We also observed that artesunate kills parasites faster at higher concentrations, which is not discernible from the traditional parasite clearance curve and that each subsequent dose of artesunate maintains its killing effect. Furthermore, based on measures of parasite viability, we could accurately predict the in vivo recrudescence of infection. Finally, using pharmacometrics modeling, we show that the apparent differences in the antimalarial activity of artesunate in mice and humans are partly explained by differences in host removal of dead parasites in the two hosts. However, these differences, along with different pharmacokinetic profiles, do not fully account for the differences in activity. (This study has been registered with the Australian New Zealand Clinical Trials Registry under identifier ACTRN12617001394336.).
- Published
- 2022
- Full Text
- View/download PDF
23. Parasite-Host Dynamics throughout Antimalarial Drug Development Stages Complicate the Translation of Parasite Clearance.
- Author
-
Burgert L, Zaloumis S, Dini S, Marquart L, Cao P, Cherkaoui M, Gobeau N, McCarthy J, Simpson JA, Möhrle JJ, and Penny MA
- Subjects
- Animals, Mice, Mice, SCID, Plasmodium berghei, Plasmodium falciparum, Antimalarials pharmacology, Antimalarials therapeutic use, Malaria, Falciparum drug therapy, Parasites
- Abstract
Ensuring continued success against malaria depends on a pipeline of new antimalarials. Antimalarial drug development utilizes preclinical murine and experimental human malaria infection studies to evaluate drug efficacy. A sequential approach is typically adapted, with results from each stage informing the design of the next stage of development. The validity of this approach depends on confidence that results from murine malarial studies predict the outcome of clinical trials in humans. Parasite clearance rates following treatment are key parameters of drug efficacy. To investigate the validity of forward predictions, we developed a suite of mathematical models to capture parasite growth and drug clearance along the drug development pathway and estimated parasite clearance rates. When comparing the three infection experiments, we identified different relationships of parasite clearance with dose and different maximum parasite clearance rates. In Plasmodium berghei -NMRI mouse infections, we estimated a maximum parasite clearance rate of 0.2 (1/h); in Plasmodium falciparum -SCID mouse infections, 0.05 (1/h); and in human volunteer infection studies with P. falciparum , we found a maximum parasite clearance rate of 0.12 (1/h) and 0.18 (1/h) after treatment with OZ439 and MMV048, respectively. Sensitivity analysis revealed that host-parasite driven processes account for up to 25% of variance in parasite clearance for medium-high doses of antimalarials. Although there are limitations in translating parasite clearance rates across these experiments, they provide insight into characterizing key parameters of drug action and dose response and assist in decision-making regarding dosage for further drug development., (Copyright © 2021 Burgert et al.)
- Published
- 2021
- Full Text
- View/download PDF
24. Retrospective Analysis Using Pharmacokinetic/Pharmacodynamic Modeling and Simulation Offers Improvements in Efficiency of the Design of Volunteer Infection Studies for Antimalarial Drug Development.
- Author
-
Andrews KA, Owen JS, McCarthy J, Wesche D, Gobeau N, Grasela TH, and Möhrle JJ
- Subjects
- Antimalarials pharmacokinetics, Cohort Studies, Computer Simulation, Dose-Response Relationship, Drug, Healthy Volunteers, Humans, Malaria parasitology, Plasmodium pathogenicity, Research Design, Retrospective Studies, Antimalarials administration & dosage, Clinical Trials, Phase I as Topic, Malaria drug therapy, Models, Biological, Plasmodium drug effects
- Abstract
Volunteer infection studies using the induced blood stage malaria (IBSM) model have been shown to facilitate antimalarial drug development. Such studies have traditionally been undertaken in single-dose cohorts, as many as necessary to obtain the dose-response relationship. To enhance ethical and logistic aspects of such studies, and to reduce the number of cohorts needed to establish the dose-response relationship, we undertook a retrospective in silico analysis of previously accrued data to improve study design. A pharmacokinetic (PK)/pharmacodynamic (PD) model was developed from initial fictive-cohort data for OZ439 (mixing the data of the three single-dose cohorts as: n = 2 on 100 mg, 2 on 200 mg, and 4 on 500 mg). A three-compartment model described OZ439 PKs. Net growth of parasites was modeled using a Gompertz function and drug-induced parasite death using a Hill function. Parameter estimates for the PK and PD models were comparable for the multidose single-cohort vs. the pooled analysis of all cohorts. Simulations based on the multidose single-cohort design described the complete data from the original IBSM study. The novel design allows for the ascertainment of the PK/PD relationship early in the study, providing a basis for rational dose selection for subsequent cohorts and studies., (© 2020 The Authors. Clinical and Translational Science published by Wiley Periodicals LLC on behalf of the American Society for Clinical Pharmacology and Therapeutics.)
- Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.